Hana M. El Sahly , Evan J. Anderson , Lisa A. Jackson , Kathleen M. Neuzil , Robert L. Atmar , David I. Bernstein , Wilbur H. Chen , C. Buddy Creech , Sharon E. Frey , Paul Goepfert , Jeffery Meier , Varun Phadke , Nadine Rouphael , Richard Rupp , Jack T. Stapleton , Paul Spearman , Emmanuel B. Walter , Patricia L. Winokur , Inci Yildirim , Tracie L. Williams , Paul C. Roberts
{"title":"抗神经氨酸酶和抗血凝素柄对不同甲型H7N9流感疫苗方案的反应","authors":"Hana M. El Sahly , Evan J. Anderson , Lisa A. Jackson , Kathleen M. Neuzil , Robert L. Atmar , David I. Bernstein , Wilbur H. Chen , C. Buddy Creech , Sharon E. Frey , Paul Goepfert , Jeffery Meier , Varun Phadke , Nadine Rouphael , Richard Rupp , Jack T. Stapleton , Paul Spearman , Emmanuel B. Walter , Patricia L. Winokur , Inci Yildirim , Tracie L. Williams , Paul C. Roberts","doi":"10.1016/j.vaccine.2024.126689","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Pandemic influenza vaccine development focuses on the hemagglutinin (HA) antigen for potency and immunogenicity. Antibody responses targeting the neuraminidase (NA) antigen, or the HA stalk domain have been implicated in protection against influenza. Responses to the NA and HA-stalk domain following pandemic inactivated influenza are not well characterized in humans.</div></div><div><h3>Material and methods</h3><div>In a series of clinical trials, we determine the vaccines' NA content and demonstrate that NA inhibition (NAI) antibody responses increase in a dose-dependent manner following a 2-dose priming series with AS03-adjuvanted influenza A(H7N9) inactivated vaccine (A(H7N9) IIV). NAI antibody responses also increase with interval extension of the 2-dose priming series or following a 5-year delayed boost with a heterologous adjuvanted A(H7N9) IIV. Neither concomitant seasonal influenza vaccination given simultaneously or sequentially, nor use of heterologous A(H7N9) IIVs in the 2-dose priming series had an appreciable effect on NAI antibody responses. Anti-HA stalk antibody responses were minimal and not durable.</div></div><div><h3>Conclusions</h3><div>We provide evidence for strategies to improve anti-neuraminidase responses which can be further standardized for pandemic preparedness.</div></div><div><h3>Clinical Trial Registry Numbers</h3><div><span><span>NCT03312231</span><svg><path></path></svg></span>, <span><span>NCT03318315</span><svg><path></path></svg></span>, <span><span>NCT03589807</span><svg><path></path></svg></span>, <span><span>NCT03738241</span><svg><path></path></svg></span>.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"47 ","pages":"Article 126689"},"PeriodicalIF":4.5000,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens\",\"authors\":\"Hana M. El Sahly , Evan J. Anderson , Lisa A. Jackson , Kathleen M. Neuzil , Robert L. Atmar , David I. Bernstein , Wilbur H. Chen , C. Buddy Creech , Sharon E. Frey , Paul Goepfert , Jeffery Meier , Varun Phadke , Nadine Rouphael , Richard Rupp , Jack T. Stapleton , Paul Spearman , Emmanuel B. Walter , Patricia L. Winokur , Inci Yildirim , Tracie L. Williams , Paul C. Roberts\",\"doi\":\"10.1016/j.vaccine.2024.126689\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>Pandemic influenza vaccine development focuses on the hemagglutinin (HA) antigen for potency and immunogenicity. Antibody responses targeting the neuraminidase (NA) antigen, or the HA stalk domain have been implicated in protection against influenza. Responses to the NA and HA-stalk domain following pandemic inactivated influenza are not well characterized in humans.</div></div><div><h3>Material and methods</h3><div>In a series of clinical trials, we determine the vaccines' NA content and demonstrate that NA inhibition (NAI) antibody responses increase in a dose-dependent manner following a 2-dose priming series with AS03-adjuvanted influenza A(H7N9) inactivated vaccine (A(H7N9) IIV). NAI antibody responses also increase with interval extension of the 2-dose priming series or following a 5-year delayed boost with a heterologous adjuvanted A(H7N9) IIV. Neither concomitant seasonal influenza vaccination given simultaneously or sequentially, nor use of heterologous A(H7N9) IIVs in the 2-dose priming series had an appreciable effect on NAI antibody responses. Anti-HA stalk antibody responses were minimal and not durable.</div></div><div><h3>Conclusions</h3><div>We provide evidence for strategies to improve anti-neuraminidase responses which can be further standardized for pandemic preparedness.</div></div><div><h3>Clinical Trial Registry Numbers</h3><div><span><span>NCT03312231</span><svg><path></path></svg></span>, <span><span>NCT03318315</span><svg><path></path></svg></span>, <span><span>NCT03589807</span><svg><path></path></svg></span>, <span><span>NCT03738241</span><svg><path></path></svg></span>.</div></div>\",\"PeriodicalId\":23491,\"journal\":{\"name\":\"Vaccine\",\"volume\":\"47 \",\"pages\":\"Article 126689\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-02-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vaccine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0264410X24013719\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X24013719","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens
Introduction
Pandemic influenza vaccine development focuses on the hemagglutinin (HA) antigen for potency and immunogenicity. Antibody responses targeting the neuraminidase (NA) antigen, or the HA stalk domain have been implicated in protection against influenza. Responses to the NA and HA-stalk domain following pandemic inactivated influenza are not well characterized in humans.
Material and methods
In a series of clinical trials, we determine the vaccines' NA content and demonstrate that NA inhibition (NAI) antibody responses increase in a dose-dependent manner following a 2-dose priming series with AS03-adjuvanted influenza A(H7N9) inactivated vaccine (A(H7N9) IIV). NAI antibody responses also increase with interval extension of the 2-dose priming series or following a 5-year delayed boost with a heterologous adjuvanted A(H7N9) IIV. Neither concomitant seasonal influenza vaccination given simultaneously or sequentially, nor use of heterologous A(H7N9) IIVs in the 2-dose priming series had an appreciable effect on NAI antibody responses. Anti-HA stalk antibody responses were minimal and not durable.
Conclusions
We provide evidence for strategies to improve anti-neuraminidase responses which can be further standardized for pandemic preparedness.
期刊介绍：
Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
